On a roll, Genentech inks discovery deals with Skyhawk, Convelo

fiercebiotech | July 16, 2019

Looks like someone ate their Wheaties. Genentech started Tuesday with a $1 billion biobucks deal with GPCR specialist Sosei Heptares and before the morning was out followed it with two more: one focused on cancer and neurodegenerative diseases with Skyhawk Therapeutics and one around neurological disorders with Convelo Therapeutics. Skyhawk will use its SkySTAR technology to discover and develop small molecules that modulate RNA splicing to treat “certain oncology and neurological disease targets,” Skyhawk said in a statement. Genentech picks up the worldwide rights to develop and market drugs for multiple targets in exchange for an upfront free and the promise of future payments and royalties. No specifics were given, but Skyhawk said it could receive up to $2 billion in total. The agreement grants Genentech an exclusive worldwide license to develop and commercialize potential therapeutics directed to multiple targets while Skyhawk receives an upfront payment and is eligible to receive future payments and royalties. As part of the agreement, Genentech will be responsible for clinical development and commercialization. "Modulation of RNA splicing represents a novel approach for difficult-to-treat diseases," said James Sabry, M.D., Ph.D., global head of pharma partnering at Roche, in the statement. "Skyhawk has developed unique expertise in splicing biology, and we are excited to work with their team to discover potential new medicines for patients with cancer and neurodegenerative diseases." Skyhawk’s SkySTAR tech—short for Small molecule Therapeutics for Alternative splicing of RNA—is designed to target specific binding pocket regions of RNA. These sites can be left out during key steps in the RNA splicing process, causing mis-splicing. The company hopes reversing this skipping could treat the underlying causes of various diseases.

Spotlight

Cyclosis, or cytoplasmic streaming, occurs in plants, animals, fungi and protists. Plant cells are much larger than animal cells and rely heavily on cyclosis to distribute nutrients, metabolites, genetic information throughout cell.

Spotlight

Cyclosis, or cytoplasmic streaming, occurs in plants, animals, fungi and protists. Plant cells are much larger than animal cells and rely heavily on cyclosis to distribute nutrients, metabolites, genetic information throughout cell.

Related News

CELL AND GENE THERAPY

ElevateBio Announces Issuance of U.S. Patent Providing Protection for RNA-Guided Nucleases Identified through its Life Edit Gene Editing Platform

ElevateBio | November 25, 2021

ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing platform. Life Edit is an ElevateBio company and holds an array of novel RGNs and base editors. "This patent issuance marks an important milestone for the Life Edit gene editing platform and is an acknowledgement of the uniqueness of our powerful suite of editing systems. ElevateBio will continue to build and strengthen our portfolio of patents surrounding our enabling platforms, which also include iPSCs, viral vector, and cell and protein engineering, that offer critical technologies and capabilities to facilitate the development of next-generation cell and gene therapies.” Mitchell Finer, Ph.D., President, R&D of ElevateBio and Chief Executive Officer of Life Edit This patent is directed to compositions of polynucleotides encoding various RGN polypeptides, CRISPR systems comprising guide RNAs and such RGN polypeptides, as well as methods for binding, cleaving and modifying a target DNA sequence of interest with the use of these novel RGNs and one or more guide RNAs. About ElevateBio ElevateBio is a cell and gene therapy technology company designed to power the development and manufacturing of transformative cell and gene therapies. ElevateBio has assembled industry-leading talent, built world-class facilities, and integrated diverse technology platforms necessary to drive innovation and commercialization of cell, gene, and regenerative therapies. ElevateBio has built an initial technology stack, including gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering, that can be leveraged across the entire portfolio and by strategic partners. At the center of the business model is ElevateBio BaseCamp, a centralized research and development and manufacturing company that offers R&D, process development, and Current Good Manufacturing Practice manufacturing capabilities. ElevateBio is focused on increasing long-term collaborations with industry partners while also developing its own highly innovative cell and gene therapies. ElevateBio's team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.

Read More

LyGenesis Announces Four Peer-reviewed Papers Are Published on Its Organ Regeneration Technology

LyGenesis | August 28, 2020

LyGenesis, Inc., a biotechnology company focused on regenerative medicine, announced today that four peer-reviewed papers have been published on its organ regeneration technology. LyGenesis' lead development asset is liver regeneration, which was the focus of the first two papers. Development of Ectopic Livers by Hepatocyte Transplantation into Swine Lymph Nodes by Fontes et al. was published this month in Liver Transplantation, demonstrating that functional mini-livers could be grown using the lymph node as a bioreactor. In this swine model using surgically-induced liver injuries, liver cells were isolated from the animals and then transplanted into lymph nodes in the abdominal region of the animal. In 100% of the animals the transplanted liver cells engrafted into the lymph nodes, proliferated, and formed ectopic mini-livers, which had the same structure and function as native liver tissue. The cell transplant procedure was safe, well tolerated, and as expected, the amount of liver mass generated by the ectopic livers was proportional to the degree of the native liver's damage.

Read More

CELL AND GENE THERAPY

Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facilit

BrainStorm Cell Therapeutics | October 26, 2020

Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that BrainStorm has selected RR&D as its partner to expedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn® (autologous MSC-NTF) in the U.S. BrainStorm is investigating NurOwn as a potential treatment for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). BrainStorm's most advanced clinical program for NurOwn is in ALS, which is currently being evaluated in a pivotal Phase 3 clinical trial. BrainStorm seeks to locate, design and construct a new commercial manufacturing facility in the U.S. to prepare for potential commercialization. RR&D, a three-firm services alliance consisting of EwingCole, Facility Logix and Biggins, Lacy, Shapiro & Company, will identify the location and develop the design of BrainStorm's new commercial manufacturing facility.

Read More